摘要
目的:研究肝细胞癌合并门静脉高压的肝切除术治疗效果及安全性。方法:回顾分析168例肝细胞癌患者的临床资料,按是否合并门静脉高压分为合并组(51例)与未合并组(117例),比较两组术后1、3、5年生存率。结果:合并组术后3年、5年生存率(45.10%、31.37%)均低于未合并组(66.67%、47.86%)(P=6.891 5、P=3.944 0)。合并组肝段切除≥3段患者术后1、3、5年生存率(67.57%、37.84%、29.73%)均低于未合并组(84.15%、67.07%、51.22%)(P=4.222 8、P=8.944 6、P=4.766 6)。结论:肝切除术治疗肝细胞癌合并门静脉高压,需严格选择患者,控制肝段切除范围。
Objective：To study the clinical efficacy and safety of liver resection for patients with portal hypertension and hepa-tocellular carcinoma. Methods：Retrospectively analyzed the clinical data of 168 patients with hepatocellular carcinoma,51 cases of pa-tients combined with portal hypertension were divided into combined group,and 117 cases with no combination were in non-combined group. The survival rates were compared 1,3,5 years after the surgery respectively. Results：The survival rates of combined group （3-year 45. 10%,5-year 31. 37%） were lower than those of non-combined group （3-year 66. 67%,5-year 47. 86%） （P=6. 891 5,P=3. 944 0）. Patients with liver section≥3 segments in combined group had lower survival rates than non-combined group 1,3,5 years after the surgery respectively （67. 57%,37. 84%,29. 73% and 84. 15%,67. 07%,51. 22%） （ P=4. 222 8,P=8. 944 6,P=4. 766 6）. Conclusion：Liver resection for hepatocellular carcinoma with portal hypertension should strictly select patients and control the he-patic resection range.
出处
《川北医学院学报》
CAS
2015年第2期212-216,共5页
Journal of North Sichuan Medical College
关键词
肝细胞癌
合并
门静脉高压
肝切除术
疗效
安全性
Hepatocellular carcinoma
Merger
Portal hypertension
Liver resection
Curative effect
Security
